Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) CFO Michael Secora sold 15,000 shares of the business’s stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $6.35, for a total value of $95,250.00. Following the transaction, the chief financial officer now directly owns 1,340,968 shares of the company’s stock, valued at $8,515,146.80. The transaction was disclosed in a legal filing with the SEC, which is available through this link.
Michael Secora also recently made the following trade(s):
- On Tuesday, July 9th, Michael Secora sold 15,000 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $7.32, for a total value of $109,800.00.
- On Thursday, June 13th, Michael Secora sold 15,000 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $9.32, for a total transaction of $139,800.00.
Recursion Pharmaceuticals Price Performance
RXRX stock opened at $6.74 on Friday. The business has a 50 day moving average price of $7.89 and a 200 day moving average price of $9.19. The company has a quick ratio of 4.65, a current ratio of 6.07 and a debt-to-equity ratio of 0.04. The stock has a market cap of $1.60 billion, a price-to-earnings ratio of -4.21 and a beta of 0.83. Recursion Pharmaceuticals, Inc. has a fifty-two week low of $4.97 and a fifty-two week high of $15.74.
Hedge Funds Weigh In On Recursion Pharmaceuticals
Large investors have recently bought and sold shares of the stock. Mubadala Investment Co PJSC acquired a new stake in shares of Recursion Pharmaceuticals during the fourth quarter worth about $128,041,000. Sumitomo Mitsui Trust Holdings Inc. lifted its stake in Recursion Pharmaceuticals by 161.2% in the fourth quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 9,203,780 shares of the company’s stock valued at $90,749,000 after buying an additional 5,680,656 shares during the last quarter. Nikko Asset Management Americas Inc. boosted its holdings in shares of Recursion Pharmaceuticals by 161.2% in the fourth quarter. Nikko Asset Management Americas Inc. now owns 9,203,780 shares of the company’s stock valued at $90,565,000 after acquiring an additional 5,680,656 shares during the period. ARK Investment Management LLC grew its position in shares of Recursion Pharmaceuticals by 14.5% during the second quarter. ARK Investment Management LLC now owns 28,142,918 shares of the company’s stock worth $211,072,000 after acquiring an additional 3,555,357 shares during the last quarter. Finally, Norges Bank acquired a new position in shares of Recursion Pharmaceuticals in the 4th quarter valued at $34,825,000. Institutional investors and hedge funds own 89.06% of the company’s stock.
Wall Street Analysts Forecast Growth
Several research analysts have commented on RXRX shares. KeyCorp lowered their price target on shares of Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating for the company in a report on Thursday, July 11th. Needham & Company LLC decreased their price objective on shares of Recursion Pharmaceuticals from $17.00 to $16.00 and set a “buy” rating for the company in a research report on Friday, August 9th.
View Our Latest Stock Report on Recursion Pharmaceuticals
About Recursion Pharmaceuticals
Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.
Read More
- Five stocks we like better than Recursion Pharmaceuticals
- What Does a Stock Split Mean?
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- MarketBeat Week in Review – 8/12 – 8/16
- What is a Bond Market Holiday? How to Invest and Trade
- JD.com Earnings Surprise: China’s Outlook Better Than Expected
Receive News & Ratings for Recursion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recursion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.